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Abstract
Hypoxia, which leads to dysfunctional cell metabolism, and
complement activation both play central roles in the
pathogenesis of rheumatoid arthritis (RA). Recent studies have
reported that mice deficient for the complement-inhibitory
protein CD59 show enhanced susceptibility to antigen-induced
arthritis and reported that statins have anti-inflammatory effects
in RA. We hypothesized that the anti-inflammatory effect of
statins in RA relates in part to their ability to increase CD59
expression in hypoxic conditions and therefore to reduce
complement activation.
Flow-cytometric analysis showed that CD59 expression on
endothelial cells (EC) was unaffected by atorvastatin in normoxia
(21% O2), whereas in hypoxic conditions (1% O2) an up to
threefold dose-dependent increase in CD59 expression was
seen. This effect of hypoxia was confirmed by treatment of EC
with chemical mimetics of hypoxia. The upregulation of CD59
protein expression in hypoxia was associated with an increase in
steady-state mRNA. L-Mevalonate and geranylgeraniol reversed
the response, confirming a role for inhibition of 3-hydroxy-3-
methylglutaryl coenzyme A reductase and geranylgeranylation.
Likewise, inhibition by NG-monomethyl-L-arginine and NG-nitro-
L-arginine methyl ester confirmed that CD59 upregulation in
hypoxia was nitric oxide dependent. The expression of another
complement-inhibitory protein, decay-accelerating factor (DAF),
is known to be increased by atorvastatin in normoxia; this
response was also significantly enhanced under hypoxic
conditions. The upregulation of CD59 and DAF by atorvastatin
in hypoxia prevented the deposition of C3, C9 and cell lysis that
follows exposure of reoxygenated EC to serum. This
cytoprotective effect was abrogated by inhibitory anti-CD59 and
anti-DAF mAbs. The modulation of EC CD59 and DAF by statins
under hypoxic conditions therefore inhibits both early and late
complement activation and may contribute to the anti-
inflammatory effects of statins in RA.
Introduction
Analysis of the rheumatoid joint reveals it to be a hypoxic envi-
ronment with mean intra-articular PO2 values as low as 13
mmHg [1,2]. This reflects in part the influence of synovial cell
proliferation and increased metabolic demand. In addition,
despite increased angiogenesis, the location of capillaries
deep within the synovium and the relatively reduced capillary
density result in inadequate tissue perfusion [3]. This is further
exacerbated by movement, which increases the intra-articular
pressure and results in periodic microvessel occlusion and
cycles of hypoxia–reoxygenation [2]. The latter leads to
chronic oxidative stress, to generation of reactive oxygen spe-
cies [1,2] and to enhanced expression of proinflammatory
mediators including cyclooxygenase-2-derived nociceptive
CIP = complement-inhibitory protein; CoCl2 = cobalt chloride; DAF = decay-accelerating factor; DFO = desferrioxamine; EC = endothelial cells; HIF 
= hypoxia-inducible factor; HMG-CoA = 3-hydroxy-3-methylglutaryl coenzyme A; HUVEC = human umbilical vein endothelial cells; IL = interleukin; L-
NAME = NG-nitro-L-arginine methyl ester; L-NMMA = NG-monomethyl-L-arginine; mAb = monoclonal antibody; MAC = membrane attack complex; 
MCP = membrane cofactor protein; NF = nuclear factor; NO = nitric oxide; RA = rheumatoid arthritis; PCR = polymerase chain reaction; RFI = relative 
fluorescence intensity; VBSG = veronal buffered saline/1% gelatin.Arthritis Research & Therapy    Vol 8 No 4    Kinderlerer et al.
Page 2 of 12
(page number not for citation purposes)
eicosanoids and matrix metalloproteinases [4,5]. Hypoxic con-
ditions within the rheumatoid joint induce expression of the
principal regulator of the adaptive response to hypoxia,
hypoxia-inducible factor (HIF). The HIF-1α and HIF-2α levels
are increased in synovial fibroblasts, macrophages and
endothelial cells (EC) [6], and HIF-1α expression has been
identified in the lining and sublining layer of rheumatoid syn-
ovium [7].
Increased levels of complement activation products are
present in the synovium, serum and synovial fluid of rheuma-
toid arthritis (RA) patients and correlate with disease activity
[8,9]. Deposition of C3 and the C5b-9 membrane attack com-
plex (MAC) has been demonstrated in the synovial lining layer
and on EC in the synovium and rheumatoid nodules [10-12].
Potential triggers for complement activation include rheuma-
toid factor immune complexes and C-reactive protein [8]. Fur-
thermore, exposure of EC to prolonged hypoxia and
reoxygenation also results in complement activation [13],
which may represent an additional means by which the com-
plement cascade is activated in the rheumatoid joint.
Deposition of the MAC may exert proinflammatory effects, pro-
proliferative effects and proapoptotic effects on synovial cells
and EC, and may modulate leukocyte recruitment [14]. The
MAC induces prostaglandin E2 release from rheumatoid syno-
vial cells [15]. Proinflammatory actions on EC are mediated
through activation of NF-κB, through induction of E-selectin
and intercellular adhesion molecule-1 expression [16], and
through release of chemokines including monocyte chemoat-
tractant protein-1 and IL-8 [14,17].
The membrane-bound complement regulatory proteins decay-
accelerating factor (DAF, CD55), membrane cofactor protein
(MCP, CD46), complement receptor-1 and CD59 provide
protection from autologous complement-mediated injury [18].
DAF and MCP act at the level of the C3 convertase. In con-
trast, CD59 inhibits the terminal pathway of complement acti-
vation, preventing the incorporation of C9 into the MAC [18].
While DAF expression is increased in the rheumatoid syn-
ovium [10], expression of CD59 is significantly decreased on
the synovial lining, stromal cells and EC [11]. Moreover, injec-
tion into the rat knee joint of an anti-rat CD59 mAb induces a
spontaneous complement-dependent arthritis [19], and
CD59-deficient mice are prone to enhanced antigen-induced
arthritis [20].
We have previously reported that, under normoxic conditions,
statins (3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors) significantly upregulate DAF expression
but not CD59 expression on EC, resulting in protection
against complement-mediated injury [21]. In vitro experiments
have revealed, however, that the effect of statins on endothe-
lial function may be enhanced by hypoxia [22]. Furthermore,
two of three recent studies have demonstrated clinically
apparent anti-inflammatory effects of statins in rodent models
of inflammatory arthritis and in one model in patients with RA
[23-26]. These findings led us to explore the hypothesis that,
under prolonged hypoxic conditions such as those present in
the rheumatoid joint, statins are able to enhance expression of
CD59, so minimizing generation of the C5b-9 MAC and its
proinflammatory consequences. Vascular EC represented a
cell type on which to test this hypothesis, because the
endothelium is exposed to hypoxia, as evidenced by expres-
sion of HIF-1α [6], and represents a major site of complement
deposition in the rheumatoid joint [9].
In the present study, we show for the first time that statins can
upregulate CD59 on EC in hypoxia and that hypoxic condi-
tions also enhance statin-induced DAF induction. These com-
bined effects result in significantly enhanced protection
against complement activation and may represent an impor-
tant novel contributory mechanism to the anti-inflammatory
effects of statins in RA.
Materials and methods
Monoclonal antibodies and other reagents
CD59 mAb (IgG1) Bric 229 was purchased from the Interna-
tional Blood Group Reference Laboratory (Bristol, UK). Anti-
DAF mAb 1H4 (IgG1) and anti-MCP mAb TRA-2-10 (IgG1)
were gifts from D Lublin and J Atkinson, respectively (Wash-
ington University School of Medicine, St Louis, MO, USA).
Atorvastatin and lovastatin were from Merck Biosciences Ltd
(Nottingham, UK). Lovastatin was chemically activated before
use by alkaline hydrolysis. Pre-activated mevastatin, NG-mon-
omethyl-L-arginine (L-NMMA), NG-nitro-L-arginine methyl
ester (L-NAME) and geranylgeraniol were from BIOMOL (Ply-
mouth Meeting, PA, USA). Other products were obtained from
Sigma (Poole, UK). In all experiments, EC were also treated
with the appropriate drug vehicle controls.
Endothelial cell isolation and culture
Human umbilical vein endothelial cells (HUVEC) were isolated
and cultured as described previously [27]. For hypoxia experi-
ments, confluent monolayers in tissue culture plates were cul-
tured in a hypoxic gas mixture consisting of 1% O2, 94% N2
and 5% CO2 in a Galaxy Rincubator (Wolf Laboratories, York,
UK) or in a hypoxic chamber with gloveport access (Ruskinn
Technologies, Cincinnati, OH, USA). The chemical mimetics
of hypoxia, cobalt chloride (CoCl2) and desferrioxamine (DFO)
(both from Sigma), were added to EC cultures 30 minutes
prior to the addition of atorvastatin and remained throughout
the experiment. Our human tissue protocols were approved by
the hospital Research Ethics Committee.
Flow cytometry
Flow cytometry was performed as described previously [27].
Pharmacological antagonists were added 60 minutes before
the addition of statins. In some experiments the results are
expressed as the relative fluorescence intensity (RFI), repre-Available online http://arthritis-research.com/content/8/4/R130
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senting the mean fluorescence intensity with test mAb divided
by the mean fluorescence intensity using an isotype-matched
irrelevant mAb. Cell viability was assessed by examination of
EC monolayers using phase-contrast microscopy, cell count-
ing and estimation of trypan blue exclusion.
Western blotting
HUVEC were lysed in urea–sodium dodecyl sulphate buffer
(6.7 M urea, 10 mM Tris–Cl (pH 6.8), 1 mM dithiothreitol, 10%
glycerol, 1% sodium dodecyl sulphate). Extracts were normal-
ized for protein content, were resolved by SDS-PAGE and
were transferred onto polyvinylidene difluoride membrane.
Blots were probed with mouse mAbs against HIF-1α (54),
HIF-2α (190b) (Transduction Labs, Lexington, KY, USA) and
α-tubulin (Sigma), followed by a horseradish peroxidase-con-
jugated secondary anti-mouse antibody (DAKO, Ely, UK) and
detection with the ECL Plus system (Amersham Biosciences,
Little Chalfont, UK).
Northern blotting and real-time PCR
HUVEC were exposed to 1% O2 and treated with atorvastatin
for the indicated times and then RNA was extracted using the
RNeasy kit (Qiagen Ltd, Crawley, UK). Total RNA was sepa-
rated on a 1% agarose/formaldehyde gel, transferred over-
night to Hybond-N nylon membranes (Amersham
Biosciences) and was analysed by specific hybridization to a
radiolabelled cDNA probe for human CD59 (gift from H Wald-
mann, University of Oxford, UK) as described previously [27].
Integrated density values for each band were obtained with an
Alpha Innotech ChemiImager 5500 (Alpha Innotech, San
Leandro, CA, USA), normalized with respect to the 28S band
on ethidium bromide-stained rRNA loading patterns and
expressed as the percentage change from control.
Quantitative real-time PCR was carried out using an iCycler
(BioRad, Hercules, CA, USA). DNase-1-digested total RNA (1
μg) was reverse transcribed using 1 μM oligo-dT and Super-
script reverse transcriptase (Invitrogen, Paisley, UK), accord-
ing to the manufacturers' instructions. For measurement of
CD59 and β-actin, cDNA was amplified in a 25 μl reaction
containing 5 μl cDNA template, 12.5 μl iSYBR supermix (Bio-
Rad), and 0.5 pmol each sense and 0.5 pmol each antisense
gene-specific primer. The volume was adjusted to 25 μl with
ddH2O. The primer sequences used were as follows: β-actin
forward, GAGCTACGAGCTGCCTGACG; β-actin reverse,
GTAGTTTCGTGGATGCCACAGGACT; CD59 forward,
ATGCGTGTCTCATTAC; and CD59 reverse TTCTCTGA-
TAAGGATGTC. The cycling parameters were 3 minutes at
95°C followed by 40 cycles of 95°C for 10 seconds and of
56°C for 45 seconds. In experiments designed to assess the
mRNA stability, EC were pretreated with actinomycin D (2 μg/
ml).
Complement deposition and lysis assays
Cell surface C3 and C9 deposition was assessed by flow
cytometry. HUVEC were incubated in 1% or 21% O2 for 48
hours with or without atorvastatin and were then reoxygenated
for 3 hours. For analysis of the C3 binding, EC were sus-
pended in veronal buffered saline containing 0.1% gelatin
(VBSG), in 20% C5-deficient serum (Sigma) or in 20% heat-
inactivated serum. For analysis of C9 deposition, cells were
resuspended in VBSG, in 20% normal human serum or in
heat-inactivated serum. EC were incubated with serum for 90
minutes (C3 binding) and for 2 hours (C9 binding) at 37°C.
Flow-cytometric assessment of C3 binding was detected with
fluorescein isothiocyanate-conjugated anti-C3 (1:40; DAKO),
and C9 binding was assessed with mouse anti-human C5b-
C9 (Technoclone, Vienna, Austria).
Complement-mediated cell lysis was measured by assessing
the percentage of cells permeable to propidium iodide using
flow cytometry, following exposure to rabbit serum (Serotec,
Oxford, UK). HUVEC exposed to the same conditions as for
C9 binding were treated with the inhibitory mAbs 1H4 [28]
and Bric 229 [29] (20 μg/ml) in VBSG. These HUVEC were
then incubated with VBSG, with 20% rabbit serum or with
heat-inactivated rabbit serum for 90 minutes at 37°C. The cells
were then washed and propidium iodide (final concentration
50 μg/ml) was added. The percentage of cells positive for pro-
pidium iodide was measured in the FL2 channel on a Beck-
man-Coulter flow cytometer (Luton, UK).
Statistical analysis
All data were expressed as the mean of the individual experi-
ments ± the standard error of the mean. Data were analysed
using one-way or two-way analysis of variance with Bonferroni
correction. Normalized data were analysed using the Wilcoxon
Rank Sum test (GraphPad Prism Software, San Diego, CA,
USA). Differences were considered significant at P < 0.05.
Results
Atorvastatin induces CD59 expression on endothelial 
cells in hypoxia
Previous studies have demonstrated that statins and hypoxia
may act both independently and synergistically to induce cyto-
protective pathways in vascular EC [30]. To explore the effect
of atorvastatin on EC CD59 expression in hypoxia, we cultured
HUVEC in 1% oxygen. We have previously demonstrated that
expression of CD59 on the surface of HUVEC is directly com-
parable with that on the surface of microvascular and arterial
EC [21,27]. Cultured EC are typically maintained at a partial
pressure of oxygen of 154 mmHg (21% O2) (at atmospheric
pressure), whereas in vivo EC are exposed to a partial pres-
sure of oxygen of 20–25 mmHg (3–5% O2) – culture in 1%
O2 (8 mmHg) therefore represents true hypoxia when com-
pared to normoxic levels of 3–5% O2 in vivo.Arthritis Research & Therapy    Vol 8 No 4    Kinderlerer et al.
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As seen in Figure 1, neither exposure to hypoxia nor treatment
with atorvastatin alone significantly affected CD59 expression.
Although on occasion atorvastatin alone led to a decrease in
CD59 expression, this did not reach significance. Treatment
with atorvastatin at concentrations up to 1 μM for 48 hours
under hypoxic conditions, however, resulted in a dose-
dependent increase in CD59 expression (Figure 1a). Treat-
ment with atorvastatin in hypoxia increased the RFI for CD59
from 287.4 ± 25.5 to 627.69 ± 147.1 (P < 0.01). The efficacy
of the hypoxic environment used was confirmed by the induc-
tion of HIF-1α and HIF-2α expression in EC following 24 hours
of culture under these conditions (Figure 1b). The increase in
expression of CD59 was first detectable at 16 hours, was
maximal at 48 hours and was sustained at 72 hours post-treat-
ment (P < 0.05) (Figure 2).
Further experiments performed under hypoxic conditions
showed that both mevastatin and lovastatin increased CD59
expression to a similar degree to atorvastatin (data not shown),
suggesting this is a statin class effect.
Chemical mimics of hypoxia enhance atorvastatin-
induced CD59 expression
We sought to confirm the effect of hypoxia on statin-induced
CD59 expression using CoCl2 and DFO. These compounds
mimic hypoxia through competition for and chelation of free
iron, respectively, stabilizing HIF-1α under normoxic condi-
tions [31].
CoCl2 alone had no effect on CD59 expression (Figure 3a),
whereas DFO increased expression by 50% (Figure 3b).
When EC were treated with atorvastatin in combination with
either CoCl2 or DFO, we observed a significant increase in
CD59; following 48 hours of treatment with atorvastatin +
CoCl2 or with atorvastatin + DFO there was an up to twofold
increase in cell surface CD59 (P < 0.05) (Figure 3). These
data further support a permissive role for hypoxia in statin-
induced CD59 expression.
CD59 mRNA is increased by exposure to hypoxia and 
atorvastatin
Northern analysis was performed to determine whether the
change in CD59 expression involved gene transcription.
mRNA was extracted from unstimulated and atorvastatin-
Figure 1
Atorvastatin enhances CD59 expression in hypoxia on endothelial cells Atorvastatin enhances CD59 expression in hypoxia on endothelial cells. 
(a) Following culture for 48 hours in 21% O2 (normoxia, open bars) or 
1% O2 (hypoxia, filled bars), in the presence of increasing concentra-
tions of atorvastatin, endothelial cell CD59 expression was measured 
by flow cytometry using the mAb BRIC 229. Bars represent the mean 
relative fluorescence intensity ± standard error of the mean, derived by 
dividing the mean fluorescence intensity obtained with test mAb by the 
mean fluorescence intensity with irrelevant isotype-matched control 
mAb (n = 4), *P < 0.05, **P < 0.01 compared with untreated controls. 
(b) Human umbilical vein endothelial cells (HUVEC) cultured for 24 
hours in 21% O2 (normoxia, N) or 1% O2 (hypoxia, Hy) were lysed and 
analysed by immunoblotting for expression of HIF-1α, HIF-2α and α-
tubulin as a loading control.
Figure 2
Kinetics for the upregulation of CD59 by atorvastatin Kinetics for the upregulation of CD59 by atorvastatin. Endothelial cells 
were treated with atorvastatin (0.5 μM) for up to 72 hours in hypoxic 
conditions (1% O2) prior to flow-cytometric analysis of CD59 expres-
sion using the mAb BRIC 229. Results are expressed as the percent-
age increase in relative fluorescence intensity (RFI) above the 
unstimulated control ± standard error of the mean (n = 3), *P < 0.05.Available online http://arthritis-research.com/content/8/4/R130
Page 5 of 12
(page number not for citation purposes)
treated HUVEC following culture under normoxic conditions
and under hypoxic (1% O2) conditions for up to 16 hours.
Northern analysis revealed multiple CD59 splice variants in
untreated EC (0 hours; Figure 4a). Quantification of mRNA
using the 2.1 kB band indicated a mean ± standard deviation
increase of 54 ± 17% after 8 hours of stimulation with atorv-
astatin in hypoxia, which had returned to baseline at 16 hours.
A comparison of the effect of atorvastatin treatment of EC for
8 hours in normoxic conditions and in hypoxic conditions sug-
gested that, even under normoxic conditions, steady-state
CD59 mRNA levels were increased by 20% by treatment with
atorvastatin (Figure 4b). Further experiments using quantita-
tive real-time PCR produced similar results with a mean ±
standard deviation increase of 105 ± 4.3% in CD59 mRNA
following an 8-hour treatment with atorvastatin in hypoxia. Like-
wise, atorvastatin treatment in normoxic conditions induced a
22 ± 12.5% increase in CD59 mRNA.
In light of the fact that hypoxia shortens the half-life of endothe-
lial nitric oxide (NO) synthase mRNA and that simvastatin
exerts a stabilizing effect [32], we performed quantitative real-
time PCR analysis in the presence of actinomycin D. In con-
trast to endothelial NO synthase, hypoxia did not reduce the
CD59 mRNA half-life, and treatment with atorvastatin in both
Figure 3
Effect of chemical mimetics of hypoxia on CD59 expression Effect of chemical mimetics of hypoxia on CD59 expression. HUVEC 
were treated with increasing concentrations of atorvastatin for 48 hours 
in the presence (filled bars) or absence (open bars) of (a) cobalt chlo-
ride (CoCl2) (100 μM) or (b) desferrioxamine (DFO) (100 μM). 
Endothelial cell CD59 expression was measured by flow cytometry 
using the mAb BRIC 229. Bars represent the mean ± standard error of 
the mean relative fluorescence intensity (n = 4). *P < 0.05, **P < 0.01 
compared with untreated control.
Figure 4
Atorvastatin increases CD59 mRNA levels in endothelial cells Atorvastatin increases CD59 mRNA levels in endothelial cells. (a) 
Human umbilical vein endothelial cells (HUVEC) were treated with ator-
vastatin (0.5 μM) and cultured for up to 16 hours in hypoxic conditions 
(1% O2). (b) HUVEC were cultured in normoxic (N) or hypoxic (H) con-
ditions for 8 hours in the presence (At) or absence of atorvastatin 0.25 
μM. Total RNA was isolated, and northern blots were prepared and 
probed for CD59 mRNA.Arthritis Research & Therapy    Vol 8 No 4    Kinderlerer et al.
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hypoxia and normoxia had no significant effect on CD59
mRNA stability (data not shown).
Effect of mevalonate and isoprenoid intermediates
To confirm that changes in CD59 expression following treat-
ment with statins under hypoxic conditions were a specific
response to the inhibition of HMG-CoA reductase, HUVEC
were pretreated with L-mevalonic acid, which completely
inhibited the upregulation of CD59 (P < 0.01) (Figure 5). In
light of reports that statins [33] and hypoxia [34] may increase
EC NO synthesis, the effects of the NO synthase inhibitors L-
NMMA and L-NAME were examined. As seen in Figure 5, the
presence of either L-NMMA or L-NAME significantly reduced
the upregulation by atorvastatin and the hypoxia of CD59 (P <
0.05).
Analysis of the effects of statins on NO bioavailability has sug-
gested that the isoprenoid intermediates geranylgeranyl pyro-
phosphate and geranylgeraniol, but not farnesyl
pyrophosphate or squalene, reverse statin-mediated effects.
The role of geranylgeranylation in CD59 expression was there-
fore examined. The presence of geranylgeraniol inhibited the
upregulation of CD59 to a similar degree to L-NMMA (P <
0.05) (Figure 5). To confirm that effects on CD59 expression
were lipid independent, EC were pretreated with the choles-
terol precursor squalene and this had no effect on the
response (data not shown). The concentrations of the meval-
onate pathway intermediates used have been established in
previous work [21].
Hypoxia enhances statin-induced decay-accelerating 
factor expression
We have previously reported that in normoxic conditions ator-
vastatin and simvastatin upregulate the expression of the com-
plement-inhibitory protein (CIP) DAF on EC, and that this, by
acting at the level of the C3 convertase, inhibits complement
activation on the cell surface [21]. In light of the permissive
influence of hypoxia on atorvastatin-induced CD59 expres-
sion, we sought to establish whether hypoxic conditions
increased atorvastatin-induced DAF expression.
HUVEC were treated with 0.25 μM atorvastatin for up to 48
hours, a concentration determined by previous studies to have
a suboptimal effect on DAF expression in normoxia [21] (Fig-
ure 6a). In our hands, DAF expression was not significantly
increased following exposure to 1% O2 for up to 48 hours (Fig-
ure 6a). Analysis of EC treated with 0.25 μM atorvastatin
under hypoxic conditions for 48 hours, however, demon-
strated a significant increase in DAF expression compared
with that seen under normoxic conditions (Figure 6a) OK. DAF
expression was increased to a similar degree under hypoxic
conditions by mevastatin and lovastatin (data not shown), sug-
gesting this is a statin class effect. MCP expression was also
increased by 48 hours of culture in hypoxic conditions, as pre-
viously reported [13], although the expression was unaffected
by statins (data not shown).
Further experiments using the chemical mimetics of hypoxia
demonstrated that CoCl2 alone had no effect on DAF expres-
sion (Figure 6b), whereas DFO increased expression up to
twofold (Figure 6c). When EC were treated with atorvastatin
in combination with either CoCl2 or DFO, a significant increase
in DAF expression was observed; following 48 hours of treat-
ment with atorvastatin + CoCl2, the RFI ± standard error of the
mean increased from 26.6 ± 7.4 to 47.7 ± 10.5 (P < 0.05)
(Figure 6b). Treatment of EC with atorvastatin and DFO
resulted in a sevenfold increase in DAF expression (mean RFI
± standard error of the mean, 21.9 ± 4.5 on unstimulated cells
and 131.9 ± 36.1 on EC treated with atorvastatin and DFO)
(P < 0.001) (Figure 6c). The enhanced effect of statins on EC
CD59 and DAF expression in hypoxia are further examples of
the permissive effect of hypoxia on the vasculoprotective
effect of statins [30].
Statin-induced decay-accelerating factor and CD59 
expression in hypoxia is cytoprotective
To investigate the functional significance of the changes in
CD59 and DAF expression, an in vitro model of complement
activation induced by hypoxia–reoxygenation was used [13]. A
fourfold increase in C3 deposition was detected on EC
exposed to hypoxia–reoxygenation and 20% C5-deficient
serum, when compared with those EC cultured under nor-
moxic conditions (Figure 7a). The use of C5-deficient serum
prevented the generation of the C5b-9 MAC, therefore facili-
tating investigation of the effects of DAF. Treatment of HUVEC
Figure 5
Mechanisms involved in atorvastatin-induced decay-accelerating factor  expression Mechanisms involved in atorvastatin-induced decay-accelerating factor 
expression. Human umbilical vein endothelial cells (HUVEC) were cul-
tured for 48 hours under hypoxia (1% O2) and were treated with atorv-
astatin (At) (0.5 μM) in the presence or absence of mevalonate (200 
μM), NG-monomethyl-L-arginine (L-NMMA) (500 μM), NG-nitro-L-
arginine methyl ester (L-NAME) (100 μM) and geranylgeraniol (GGOH) 
(20 μM). Endothelial cell CD59 expression was measured by flow 
cytometry using the mAb BRIC 229. Results are expressed as the per-
centage increase in relative fluorescence intensity above the hypoxic 
control (US) (n = 4). *P < 0.5, **P < 0.01 compared with untreated 
controls.Available online http://arthritis-research.com/content/8/4/R130
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with atorvastatin for 48 hours in hypoxia abolished C3 deposi-
tion on EC following reoxygenation (P < 0.05) (Figure 7a). The
dependence upon complement activation was demonstrated
by the lack of C3 deposition following exposure to heat-inacti-
vated serum.
The functional effect of a change in CD59 expression was ini-
tially assessed by analysis of C9. A 40% increase in C9 bind-
ing was observed in HUVEC exposed to hypoxia–
reoxygenation and 20% normal human serum, when com-
pared with those HUVEC cultured in normoxia, and this was
abrogated by pretreatment of EC with atorvastatin (Figure 7b)
(P < 0.05).
A propidium iodide cell-lysis assay was used to quantify the
outcome of complement activation on the EC surface. HUVEC
cultured in 1% O2 were protected by atorvastatin against reox-
ygenation-induced complement-mediated EC lysis (P  <
0.001) (Figure 7c). The importance of CD59 and DAF in this
cytoprotection was confirmed using the neutralizing, noncom-
plement fixing mAbs BRIC 229 and 1H4, respectively. Statin-
mediated protection was completely abolished by blockade of
CD59 and was partially abolished following blockade of DAF
(Figure 7c). Under hypoxic conditions, therefore, statins are
capable of protecting EC against complement deposition
through inhibition of both the C3 convertase and the MAC.
Discussion
In the rheumatoid joint, synovial tissue hypertrophy and disor-
ganized vasculature contribute to relative hypoperfusion and
hypoxia, with consequent activation of HIF [1]. In addition,
increased intra-articular pressure may cause capillary collapse
on joint movement, resulting in repeated cycles of hypoxia–
reoxygenation, chronic oxidative stress and enhanced local
inflammation [1,2]. We used human EC, in an in vitro model
system, to explore the effects of statins on complement activa-
tion in prolonged hypoxia, such as that found in the rheumatoid
joint.
Complement activation plays an important role in the patho-
genesis of RA and correlates with disease activity [8]. Immune
complexes, rheumatoid factor and C-reactive protein OK may
contribute to complement activation in the synovium [8]. In
addition to this, in vitro studies with EC [13] suggest that
cycles of hypoxia and reoxygenation within the synovium may
also exacerbate complement activation. In situ analysis has
demonstrated abundant local synthesis of C3, C3aR, C5aR
and C5b-9 at distinct sites in the synovium [9], with C3 and
C5b-9 expressed most strongly in the microvasculature,
where C5b-9 deposition may result in endothelial injury [12].
Nucleated cells, however, are relatively resistant to lysis, and
the effects of C5b-9 are more typically proinflammatory – with
generation of reactive oxygen species, upregulation of E-
selectin and intercellular adhesion molecule-1 on EC, and the
release of soluble mediators including IL-8, MCP-1 and pros-
Figure 6
Hypoxia increases atorvastatin-induced decay-accelerating factor  expression Hypoxia increases atorvastatin-induced decay-accelerating factor 
expression. Analysis of decay-accelerating factor expression on human 
umbilical vein endothelial cells (HUVEC) (a) following 48 hours culture 
in 21% O2 (open bars) or 1% O2 (filled bars) in the presence or 
absence of atorvastatin (0.25 μM). (b) and (c) HUVEC were treated 
with increasing concentrations of atorvastatin for 48 hours in the pres-
ence (filled bars) or absence (open bars) of (b) cobalt chloride (CoCl2) 
(100 μM) or (c) desferrioxamine (DFO) (100 μM). Decay-accelerating 
factor expression was measured by flow cytometry using the mAb 1H4. 
Bars represent the mean ± standard error of the mean (n = 4). *P < 
0.05, **P < 0.01 compared with untreated controls.Arthritis Research & Therapy    Vol 8 No 4    Kinderlerer et al.
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Figure 7
Atorvastatin-induced CD59 and decay-accelerating factor in hypoxia enhance endothelial cell cytoprotection Atorvastatin-induced CD59 and decay-accelerating factor in hypoxia enhance endothelial cell cytoprotection. (a) Human umbilical vein endothelial 
cells (HUVEC) were cultured under normoxic or hypoxic conditions with and without atorvastatin (0.25 μM) for 48 hours followed by 3 hours reoxy-
genation. Harvested endothelial cells (EC) were incubated with 20% C5-deficient (C5 D) serum (filled bars) or heat-inactivated (HI) normal human 
serum (NHS) (open bars) for 2 hours. C3 binding was analysed by flow cytometry and results are expressed as the percentage of C3 binding rela-
tive to that on EC exposed to C5 D in normoxia (shown as 100%). *P < 0.05 (n = 4), difference between levels of cell surface C3 deposition on EC 
cultured under hypoxic conditions in the presence or absence of atorvastatin (b) HUVEC were cultured under normoxic or hypoxic conditions with 
and without atorvastatin (0.5 μM) for 48 hours followed by 3 hours of reoxygenation. C9 binding was analysed by flow cytometry following incuba-
tion with 20% NHS (filled bars) or HI serum (open bars). Results are expressed as the percentage of C9 binding relative to that on EC exposed to 
NHS in normoxia (shown as 100%). *P < 0.05 (n = 4), difference between statin-treated and untreated EC in hypoxia.(c) HUVEC were incubated in 
1% O2 with or without atorvastatin (At) 0.5 μM for 48 hours followed by 3 hours of reoxygenation. EC were preincubated with the inhibitory mAbs 
Bric229 (CD59) and 1H4 (decay-accelerating factor) (20 μg/ml) or veronal buffered saline + 1% gelatin at 4°C. EC were then incubated with 20% 
rabbit serum or 20% HI rabbit serum at 37°C for 1 hour and propidium iodide (PI) was added prior to analysis by flow cytometry. The percentage EC 
lysis was calculated as the number of PI-positive cells expressed as a percentage of the total number of cells. **P < 0.001 (n = 4), difference 
between statin-treated and untreated EC.Available online http://arthritis-research.com/content/8/4/R130
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taglandin E2  [17,35,36], resulting in increased leukocyte
recruitment in inflammatory arthritis [15]
The statins, principally used to control lipid levels, may also
exert anti-inflammatory and immunomodulatory effects. Intrigu-
ingly, in two reports the statins displayed disease-modifying
effects in rodent models of inflammatory arthritis [23,26],
although a third study found no beneficial effect [25]. The Trial
of Atorvastatin in Rheumatoid Arthritis [24] compared atorvas-
tatin 40 mg daily with placebo, as an adjunct to existing
antirheumatic therapy, and reported a significant improvement
in the 28 joint disease activity score (DAS28) after 6 months.
In vivo studies have demonstrated that statins reduce comple-
ment-dependent leukocyte migration [37] and that they may
be protective against ischemia-reperfusion injury [38], in
which complement activation plays an important role.
In view of the synergy observed between the actions of
hypoxia and statins [30], we explored the effect of statins on
the expression and function of membrane-bound CIP on EC,
at levels of hypoxia consistent with those in the rheumatoid
joint. A variety of different cell types is exposed to hypoxia and
contributes to the pathogenesis of RA [6]. We chose to study
vascular EC, as the endothelium is the portal of entry for leu-
kocytes to the rheumatoid synovium and is particularly
exposed to deposition of C3 and C5b-9 [9]. The concentra-
tions of statins used were in the same range as those found to
have effects on hypoxic human EC in vitro [30], and are close
to those achieved in plasma following therapeutic dosing [39].
Treatment of HUVEC cultured in 1% O2 with atorvastatin, with
lovastatin or with mevastatin resulted in upregulation of CD59,
a response not seen in normoxia, where on occasion atorvas-
tatin treatment reduced CD59 expression, although this did
not reach significance. To our knowledge this is the most sig-
nificant increase in CD59 protein expression recorded on pri-
mary human EC. Although CD59 is constitutively expressed
on human vascular EC, we have failed to demonstrate signifi-
cant upregulation in response to tumour necrosis factor alpha,
interferon gamma, vascular endothelial growth factor or
thrombin [27,40], and only a minimal change has been
reported elsewhere in response to tumour necrosis factor
alpha and IL-1β [41].
We have previously reported that, under normoxic conditions,
statins upregulate EC DAF [21]. In the current study we show
that hypoxia enhances atorvastatin-induced DAF expression,
suggesting that hypoxia plays a permissive role in both CD59
and DAF upregulation by statins. Although the experiments
described were performed with HUVEC, we have found com-
parable expression and regulation of CIP on both human arte-
rial and microvascular EC [27,40].
Culture of EC in hypoxia (1% O2) is representative of the
hypoxic conditions found within the rheumatoid joint and suffi-
cient to activate HIF in EC [6]. We therefore sought to confirm
the effects of hypoxia on CD59 and DAF expression, using
agents that stabilize HIF in normoxia. Treatment of EC with
atorvastatin and chemical mimetics of hypoxia demonstrated
additive, and on occasion synergistic, increases in both CD59
and DAF. Treatment of cells with cobalt or iron chelators pre-
vents von Hippel Lindau protein binding to HIF, which is
required to target its destruction [42], thus mimicking hypoxia
by stabilizing HIF in normoxic conditions. The permissive effect
of both cobalt and iron chelation on DAF and CD59 expres-
sion suggests a role for HIF in the upregulation of DAF and
CD59 by atorvastatin in hypoxia. The reported effects of stat-
ins on HIF expression are conflicting, however, with pravasta-
tin increasing EC HIF-1 [43] and simvastatin reducing
expression in coronary arteries [44]. Interestingly, although
CD59 has not been shown to be a hypoxia-responsive gene,
microarray analysis of von Hippal Lindau regulated genes
revealed CD59 to be a von Hippal Lindau target [45].
CD59 upregulation by atorvastatin in hypoxia was dependent
upon increased steady-state mRNA, with maximal induction at
8 hours returning to baseline 16 hours post-treatment. We did
not detect any effect of atorvastatin on endothelial nitric oxide
synthase mRNA stability. A small increase in CD59 mRNA
was also seen in normoxic conditions following 8 hours of
treatment with atorvastatin, with a further increase under
hypoxic conditions. Of note, despite a small increase in mRNA,
no significant change in CD59 surface protein expression was
detectable following treatment with atorvastatin in normoxia,
raising the possibility that increased expression in hypoxic
conditions reflects an additional effect of hypoxia that facili-
tates CD59 translation or surface expression. It is noteworthy
that the upregulation by statins and hypoxia of another glyco-
sylphosphatidylinositol-anchored molecule, ecto-5' -nucleoti-
dase (CD73), relies on reduced endocytosis, as a result of
alteration in the membrane fatty acid content under hypoxic
conditions and of statin-mediated inhibition of Rho [30].
Statins also inhibit geranylgeranylation and farnesylation
through the inhibition of HMG-CoA reductase, therefore pre-
venting the post-translational modification of the GTP-binding
proteins Rho, Rac and Ras. This results in anti-inflammatory
effects including the downregulation of NF-κB activity [46],
the stabilization of endothelial nitric oxide synthase mRNA and
increased NO biosynthesis [33]. As many of the cytoprotec-
tive effects of statins in hypoxia are NO-dependent, we
explored the role of NO using L-NMMA and L-NAME, which
significantly inhibited upregulation of CD59 in hypoxia. We
also demonstrated that the regulation of CD59 by statins in
hypoxia was inhibited by mevalonate and geranylgeraniol, con-
firming a role for inhibition of HMG-CoA reductase and geran-
ylgeranylation, respectively. Furthermore, the failure of
squalene to influence the response suggested that the mech-
anism underlying the actions of the statins was cholesterol
independent. Although the effect of statins on farnesylationArthritis Research & Therapy    Vol 8 No 4    Kinderlerer et al.
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was not studied, we have previously reported that inclusion of
farnesylpyrophosphate does not inhibit statin-induced DAF
expression [21], and likewise that geranylgeranyl pyrophos-
phate and not farnesylpyrophosphate inhibit statin-induced
changes in NO bioavailability [33].
Notwithstanding this information, the precise mechanism
underlying the effects of hypoxia and NO in statin-induced
CD59 expression remains to be fully determined. We have
previously shown that statin-induced DAF expression in nor-
moxia is independent of NO [21], suggesting that a distinct
additional mechanism is activated by the combination of stat-
ins and the hypoxic microenvironment, resulting in induction of
CD59 and enhanced DAF upregulation. The involvement of
NO may reflect its ability to activate protein kinase C epsilon
[47], a protein kinase C isoenzyme capable of regulating DAF
expression [48]. Furthermore, NO is reported to inhibit phos-
phatidylinositol-specific phospholipase C, thus reducing shed-
ding of glycosylphosphatidylinositol-anchored proteins such
as CD59 and DAF [49]. Additional mechanisms are also likely
to be important and dependent upon the redox status of EC.
Other cytoprotective molecules such as adenosine may there-
fore contribute, as HUVEC exposed to hypoxia and statins
upregulate CD73 expression, releasing adenosine [22], which
can induce NO synthesis.
CD59 appears to play an important role in the joint and its
expression is reported to be reduced in rheumatoid synovium
when compared with noninflamed tissue [11]. The hypothesis
that CD59 deficiency may contribute to synovial inflammation
in RA is supported by the report that deletion of CD59a, the
murine homologue of human CD59, increased disease sever-
ity in an antigen-induced arthritis model, a phenotype that was
reversed by recombinant membrane-targeted CD59 [20].
These studies clearly implicate C5b-9 as pathogenic and
CD59 as a protective factor in murine models of RA. Comple-
ment activation therefore represents an attractive therapeutic
target in RA. Various approaches are effective in rodent mod-
els, including treatment with an anti-C5 mAb [50], soluble
complement receptor-1 and a DAF-Ig fusion protein [51,52].
Moreover, C5-deficiency protects susceptible mice (DBA/
1LacJ) against CIA [53]. Although data from human studies
are limited, anti-C5 mAb therapy has been reported safe and
effective in RA [54].
To explore the functional relevance of statin-induced CIP
expression we utilized a hypoxia-reoxygenation model [36].
The increased expression of CD59 and DAF, induced by stat-
ins under hypoxic conditions, significantly reduced comple-
ment activation and cell lysis following hypoxia–reoxygenation.
The anti-inflammatory effects of statins in RA are likely to be
multifactorial and include effects on T cells and monocyte/
macrophage function, on proinflammatory cytokine release, on
leukocyte trafficking and on generation of reactive oxygen spe-
cies [24]. The results herein suggest that modulation of com-
plement activation, through induction of membrane-bound
CIP, should be added to this list. In particular, statin-induced
CD59 expression would act to reverse the deficiency seen in
RA [11] and would minimize the proinflammatory actions of
C5b-9, which are not only confined to the vasculature but also
affect synovial cells, resulting in the release of proinflammatory
mediators [15].
Although the role of statins in RA therapy remains to be deter-
mined, they represent an attractive option. RA is associated
with chronic endothelial dysfunction and a twofold to threefold
increase in the risk of myocardial infarction. The results of the
Trial of Atorvastatin in Rheumatoid Arthritis study show that
atorvastatin significantly reduces levels of low-density lipopro-
tein-cholesterol and triglyceride in RA, while also exerting
measurable disease-modifying effects – suggesting that stat-
ins offer both vascular protection and adjunctive immunomod-
ulatory potential in RA [24]. Recognizing the preliminary nature
of the clinical data supporting a disease-modifying effect for
statins in RA and the need for in vivo confirmation of our find-
ings, we propose that the ability of statins to significantly
increase expression of membrane-bound CIP on vascular EC
under hypoxic conditions may contribute to an anti-inflamma-
tory action of statins in RA. The combined effects of DAF, at
the level of C3 and C5 convertases, and of CD59 inhibiting
the terminal attack complex has the potential to exert anti-
inflammatory and vasculoprotective effects, both in the syn-
ovium and at sites of atherogenesis.
Conclusion
We have identified a novel mechanism by which statins pro-
tect the vascular endothelium against complement deposition
following hypoxia–reoxygenation, through increased expres-
sion of CD59, via an NO-dependent and lipid-independent
pathway. This, combined with statin-induced DAF upregula-
tion, may represent an important contributory mechanism by
which statin therapy can provide both anti-inflammatory and
anti-atherogenic effects in RA.
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